MGMT and glioblastoma: Around half of glioblastomas exhibit promoter hypermethylation, leading to reduced levels of the dealkylating enzyme MGMT that specifically and directly removes alkylation lesions induced by TMZ and is, therefore, an established biomarker of TMZ effectiveness and short-term clinical response [5].